Merck and Moderna’s intismeran autogene meets its primary endpoint in the Phase 3 INTerpath-001 trial in completely resected melanoma, Ultragenyx’s Genglycos receives FDA accelerated approval as the first treatment for glycogen storage disease type Ia, argenx’s...
For years, the clinical research industry has focused heavily on one question: How do we reach more patients? Digital advertising, social media campaigns, patient advocacy partnerships, and online recruitment platforms have dramatically expanded researchers' ability...
For years, the conversation around microplastics centered on a simple question: Are they present in the human body? The answer is now increasingly clear. Microplastics have been detected in human blood, placentas, lungs, liver tissue, arterial plaque, reproductive...
Definium Therapeutics has reported positive results from its first Phase 3 LSD anxiety trial. The data push a psychedelic medicine closer to a regulatory filing in a condition that has not seen a new drug approval since 2007. The company said on 12 August that Voyage...
13 August 2026 - Panthera has opened its latest clinical trial clinic at Keele University, further strengthening its growing clinical research network across the UK and Europe. Panthera, which is the UK's largest independent Site Management Organisation (SMO),...
Tenax Therapeutics' TNX-103 misses its primary endpoint in the Phase 3 LEVEL trial in pulmonary hypertension due to heart failure with preserved ejection fraction, AbCellera's ABCL635 meets both primary efficacy endpoints in a Phase 2 trial in menopausal vasomotor...
Most Supplement Companies Skip the RCT. Here’s Why the Few That Don’t Often Get It Wrong The industry’s uncomfortable truth The global dietary supplement market is worth hundreds of billions of dollars.[1] Brands make claims about energy, cognition, immunity, and...
Neurona Therapeutics' rezanecel demonstrates durable seizure reduction past the one-year mark in drug-resistant mesial temporal lobe epilepsy at the AAN Annual Meeting, Gilead Sciences and Arcus Biosciences' TIGIT inhibitor domvanalimab fails its pivotal Phase 3 lung...
Panthera Biopartners Expands European Footprint with Acquisition of Hungary’s Leading Clinical Research Organisation, OEC Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners...
Revolution Medicines' daraxonrasib nearly doubles overall survival in previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial, Travere Therapeutics' Filspari receives FDA approval as the first-ever treatment for focal segmental...
The daraxonrasib pancreatic cancer trial results announced on 13 April 2026 represent what many in the oncology community are calling a landmark moment for one of medicine's most stubborn and lethal diseases. Revolution Medicines, a late-stage clinical oncology...
It’s ironic that the rigid nature of clinical research depends on a largely fragile variable: people. Even the most promising therapy cannot succeed in development if the study evaluating it struggles to keep participants engaged. Recruiting patients is already a...
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
International Menopause Society sets new global standards for menopause care with evidence-led framework For the first time in a decade, the International Menopause Society (IMS) has released a complete redevelopment of its global menopause recommendations. Grounded...
An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...
This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...